Zeven (dalbavancin) / RaQualia, AbbVie 
Welcome,         Profile    Billing    Logout  
 20 Diseases   6 Trials   6 Trials   1040 News 


«12345678910111213...1516»
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Evaluating the Use of Dalbavancin for Off-Label Indications. (Pubmed Central) -  Apr 22, 2022   
    Estimated cost avoidance per patient was USD 5313 and USD 1683 if traditional IV therapy would have been completed in the hospital and skilled nursing facility, respectively. (4) Dalbavancin was associated with a relatively high success rate for the treatment of off-label indications and may be a cost-effective alternative to traditional IV antibiotic therapy.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Retrospective data, Journal, Real-world evidence:  Real world utilization of Dalbavancin at a rural community emergency department. (Pubmed Central) -  Apr 9, 2022   
    Following the administration of dalbavancin for ABSSI at a rural emergency department, few patients are subsequently admitted within the following 30 days. To further decrease this number and alleviate the burden on emergency departments and hospitals, local treatment algorithms should be developed to minimize the risk of representation and hospitalization following administration.
  • ||||||||||  Nuvocid (oritavancin) / Melinta Therap, Arbelic (telavancin) / Cumberland, Zeven (dalbavancin) / RaQualia, AbbVie
    Review, Journal:  Role of membrane proteins in bacterial resistance to antimicrobial peptides. (Pubmed Central) -  Apr 8, 2022   
    Therefore, it is critical to gain a deeper understanding of the role of resistance mechanisms to minimize the consequential risks of long-term antibiotic use and misuse. Here, we summarize for the first time the current knowledge of resistance mechanisms that have been shown to cause resistance to clinically used AMPs, with particular focus on membrane proteins that have been reported to interfere with the activity of AMPs by affecting the binding of AMPs to bacteria.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, Journal, HEOR:  Effectiveness, safety and cost analysis of dalbavancin in clinical practice. (Pubmed Central) -  Apr 2, 2022   
    Our results suggest that dalbavancin is a safe and effective alternative to the off-label treatment of gram-positive infections. Its dosage facilitates early discharge and outpatient management of these patients.
  • ||||||||||  rifampicin / Generic mfg.
    Journal:  Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice. (Pubmed Central) -  Mar 26, 2022   
    The aim of this multidisciplinary opinion article is to summarize evidence supporting the use of the different anti-staphylococcal agents in terms of microbiological and pharmacological optimization according to bone penetration, anti-biofilm activity, long-term safety, and feasibility for outpatient regimens, and to provide a useful guide for clinicians in the management of patients affected by staphylococcal infections associated with orthopaedic implants Novel long-acting lipoglycopeptides, and particularly dalbavancin, alone or in combination with rifampicin, could represent the best antibiotic choice according to real-world evidence and pharmacokinetic/pharmacodynamic properties. The implementation of a multidisciplinary taskforce and close cooperation between microbiologists and clinicians is crucial for providing the best care in this scenario.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Enrollment open, Trial completion date, Trial primary completion date:  Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) (clinicaltrials.gov) -  Mar 10, 2022   
    P=N/A,  N=100, Recruiting, 
    Of note, few coagulase-negative staphylococci (CoNS) isolates were resistant to dalbavancin and susceptible to vancomycin, highlighting the importance of testing for susceptibility to dalbavancin before its administration for CoNS infections. Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, Journal:  Reaction during dalbavancin infusion: About one case (Pubmed Central) -  Mar 3, 2022   
    Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022 No abstract available
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Trial primary completion date, Gram positive:  Dalbavancin Outpatient Pilot (clinicaltrials.gov) -  Feb 24, 2022   
    P4,  N=24, Not yet recruiting, 
    No abstract available Trial primary completion date: Apr 2022 --> Apr 2023
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Trial completion date, Trial primary completion date:  Evaluation of Intravenous Dalbavancin for Peritonitis (clinicaltrials.gov) -  Feb 24, 2022   
    P=N/A,  N=10, Recruiting, 
    Trial primary completion date: Apr 2022 --> Apr 2023 Trial completion date: Sep 2021 --> Jun 2024 | Trial primary completion date: Sep 2021 --> Dec 2023
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, Journal:  Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU. (Pubmed Central) -  Jan 28, 2022   
    This case report describes a 40-year-old morbidly obese female actively using intravenous drugs who developed prolonged MRSA bacteremia without a recognizable focus. Despite partial treatment with dalbavancin, the patient developed osteomyelitis and discitis of the spine with associated epidural phlegmon, likely complications of the MRSA bacteremia.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing. (Pubmed Central) -  Jan 18, 2022   
    However, when combined with heparin, its efficacy was reduced. Therefore, we recommend that if lock therapy with frozen dalbavancin is used in the management of enterococcal C-RBSI, heparin should be added simultaneously at the time of catheter lock.
  • ||||||||||  teicoplanin / Generic mfg.
    Review, Journal:  Teicoplanin-A New Use for an Old Drug in the COVID-19 Era? (Pubmed Central) -  Dec 29, 2021   
    We believe that, due to the extensive experience of teicoplanin usage in clinical settings to treat bacterial infections and its demonstrated activity against SARS-CoV2, teicoplanin could become a drug of choice in the treatment of COVID-19 patients. Teicoplanin stops the replication of the virus and at the same time avoids the development of Gram-positive bacterial co-infections.